奧那妥珠單抗

**奧那妥珠單抗**
單株抗體
種類	Fab片段（英語：Fab fragment）
目標	散射因子受體激酶
臨床資料
ATC碼	未分配;
識別資訊
CAS號	1133766-06-9
ChemSpider	none;
UNII	MS1J9720WC;
化學資訊
化學式	C4422H6820N1168O1363S31
摩爾質量	99,147.88 g·mol−1

奧那妥珠單抗（INN：onartuzumab）是一種人源化單株抗體，設計用於治療晚期非小細胞肺癌。^[1]^[2]^[3]

奧那妥珠單抗由基因泰克公司開發，正在進行臨床試驗。^[4]^[5]^[6]^[7]

參考資料[編輯]

^ Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab (PDF). American Medical Association.
^ Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. December 2012, 1 (4): 238–53. PMC 4367550 . PMID 25806189. doi:10.3978/j.issn.2218-6751.2012.10.08.
^ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. May 2015, 15 (5): 487–9. PMID 25818471. doi:10.1586/14737140.2015.1031219 .
^ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. November 2013, 53 (11): 1103–11. PMID 23922054. S2CID 206059437. doi:10.1002/jcph.148.
^ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. November 2012, 13 (6): 500–4. PMID 23063071. doi:10.1016/j.cllc.2012.05.009.
^ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. November 2013, 31 (32): 4105–14. PMC 4878106 . PMID 24101053. doi:10.1200/JCO.2012.47.4189.
^ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. June 2015, 33 (3): 632–40. PMID 25777467. S2CID 20118425. doi:10.1007/s10637-015-0227-5.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab (PDF). American Medical Association.

[2] Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. December 2012, 1 (4): 238–53. PMC 4367550 . PMID 25806189. doi:10.3978/j.issn.2218-6751.2012.10.08.

[3] Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. May 2015, 15 (5): 487–9. PMID 25818471. doi:10.1586/14737140.2015.1031219 .

[4] Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. November 2013, 53 (11): 1103–11. PMID 23922054. S2CID 206059437. doi:10.1002/jcph.148.

[5] Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. November 2012, 13 (6): 500–4. PMID 23063071. doi:10.1016/j.cllc.2012.05.009.

[6] Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. November 2013, 31 (32): 4105–14. PMC 4878106 . PMID 24101053. doi:10.1200/JCO.2012.47.4189.

[7] Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. June 2015, 33 (3): 632–40. PMID 25777467. S2CID 20118425. doi:10.1007/s10637-015-0227-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]